Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06359340 · ClinicalTrials.gov registry record · NA

Therapy and Peer Support for Patients Taking Medication for Opioid Use Disorder

A NA study of Opioid Use Disorder, sponsored by Public Health Management Corporation.

Active
Registry status
NA
Development phase
440
Enrollment target
1
Study location

NCT06359340: Active NA study of Opioid Use Disorder, sponsored by Public Health Management Corporation.

NCT06359340 is a NA study of Opioid Use Disorder that is active but no longer recruiting, run by Public Health Management Corporation. The registered enrollment target is 440 participants, below the 4,655-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06359340, a NA study of Opioid Use Disorder, is active but no longer recruiting, sponsored by Public Health Management Corporation.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
440 participants
Enrollment target
1
Study location

Study Summary

Current clinical guidelines for medication assisted treatment (MAT) of opioid use disorder (OUD) recommend that treatment include a psychosocial component to help address psychological factors related to addiction. However, a knowledge gap exists regarding the most effective forms of psychosocial intervention and what interventions are most effective for different types of patients. This gap represents a significant barrier to the widespread implementation of effective office-based opioid treatment (OBOT) with buprenorphine, which is important to improving opioid treatment and responding to the critical needs of individuals living with OUD. The overarching goal of this patient-centered research is to address the diverse needs and preferences of OUD patients in regards to psychosocial approaches and to overcome the "one-size-fits-all" strategies that are typically used to treat OUD. Importantly, the investigators arrived at this goal, in part, through collaboration and consultation with former patients who have received different types of treatments for OUD. In this manner, patients provided important insight to inform the selection of interventions to be evaluated, patient characteristics that may differentially impact the effects of the interventions, and the patient outcomes to be examined.

Primary Outcome

Participants will provide a urine specimen at baseline and 3, 6, 9, and 12-month assessments. Investigators will use the CLIA Waived® 14-Panel Drug Test Cup and fentanyl test strip for opioids, buprenorphine, methadone, oxycodone, THC, cocaine, amphetamines, PCP, methamphetamine, benzodiazepines, and barbiturates, and MDMD. The urine sample will be delivered under the supervision of the RA who will use standard procedures to detect tampering and dilution.

Conditions Studied

Interventions

  • BEHAVIORAL Psychosocial treatment

Study Locations (1)

Pennsylvania

  • Philadelphia College of Osteopathic Medicine - Philadelphia

Trial Details

FieldValue
Enrollment Target 440 participants
Start Date 2020-03-13
Est. Completion 2026-10-31
Phase NA

What the registry record for NCT06359340 still lists

NCT06359340 is an interventional study that assigns participants to a tested intervention. The registered 440 participants enrollment target is mid-sized for trials with a published cap, below the 4,655-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (91% lower).

The record links to 1 condition, with Opioid Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which Psychosocial treatment is the first listed.

NCT06359340 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06359340 about?

NCT06359340 is a clinical study titled "Therapy and Peer Support for Patients Taking Medication for Opioid Use Disorder". Current clinical guidelines for medication assisted treatment (MAT) of opioid use disorder (OUD) recommend that treatment include a psychosocial component to help address psychological factors related to addiction. However, a knowledge gap exists regarding the most effective forms of psychosocial in...

What is the current status of trial NCT06359340?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 440 participants. The study started on 2020-03-13. Estimated completion is 2026-10-31.

What conditions does trial NCT06359340 study?

This clinical trial studies the following conditions: Opioid Use Disorder.

What interventions are being tested in trial NCT06359340?

The interventions under investigation include: Psychosocial treatment (BEHAVIORAL).

Who is sponsoring clinical trial NCT06359340?

This trial is sponsored by Public Health Management Corporation, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06359340 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Opioid Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06359340's enrollment target sits among peer trials

440 42nd of 257 higher than 216 of 257 other Opioid Use Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Opioid Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05114538 · 440 participants · NA

    Improving the Part C Early Intervention Service Delivery System for Children with ASD

  • NCT05117619 · 440 participants · NA

    The HOME Program for Individuals With Traumatic Brain Injury and Family Members

  • NCT05602194 · 440 participants · Phase 3

    Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma

  • NCT05624879 · 440 participants · NA

    Accelerated Resolution Therapy for Early Maladaptive Grief

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06359340, the US trial registry maintained by the National Library of Medicine. NCT06359340 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.